

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2021	2020	2021	2020
Grant and collaboration revenue	\$ 30	\$ 415	\$ 221	\$ 1,572
Operating expenses:				
Research and development	1,224	417	2,660	1,687
General and administrative	758	435	2,563	1,365
	<u>1,982</u>	<u>852</u>	<u>5,223</u>	<u>3,052</u>
Loss from operations	(1,952)	(437)	(5,002)	(1,480)
Other income (expense), net	1	(134)	175	(142)
Net loss	<u>\$ (1,951)</u>	<u>\$ (571)</u>	<u>\$ (4,827)</u>	<u>\$ (1,622)</u>
Loss per common share	<u>\$ (0.31)</u>	<u>\$ (0.73)</u>	<u>\$ (0.80)</u>	<u>\$ (2.85)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	Sep. 30, 2021	Dec. 31, 2020
Assets:		
Cash and cash equivalents	\$ 18,107	\$ 9,884
Other current assets	53	351
Total current assets	<u>18,160</u>	<u>10,235</u>
Property and other assets, net	180	159
Total assets	<u>\$ 18,340</u>	<u>\$ 10,394</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 336	\$ 825
Stockholders' equity	18,004	9,569
Total liabilities and stockholders' equity	<u>\$ 18,340</u>	<u>\$ 10,394</u>
Common Shares Outstanding	6,382	3,834